Clinical Trials at UM Sylvester Comprehensive Cancer Center at Coral Gables

As of July 2026, 49 paid clinical trials are recruiting at UM Sylvester Comprehensive Cancer Center at Coral Gables in Coral Gables, Florida. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

49 clinical trials at UM Sylvester Comprehensive Cancer Center at Coral Gables

·Clear filters·↓ Download CSV

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for Acute Myeloid Leukemia

22 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT05886049·Phase 1·Recruiting

Apply to this trial

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

for Metastatic Colorectal Carcinoma

60 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT05863195·Phase 3·Recruiting

Apply to this trial

Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment

for Recurrent Glioma

27 locations incl. Aurora

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05859334·Phase 2·Recruiting

Apply to this trial

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

for Oropharyngeal Cancer

28 locations incl. Corona

Sponsor: Canadian Cancer Trials Group

Sex: All·Age: 18+

Code: NCT05451004·Phase 3·Recruiting

Apply to this trial

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

for Recurrent Glioblastoma, IDH-Wildtype

Drug: Selinexor

36 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05432804·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

for Recurrent Ovarian High Grade Serous Adenocarcinoma

27 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT04633239·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

for Anatomic Stage IV Breast Cancer AJCC v8

Drug: Tremelimumab

30 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03606967·Phase 2·Recruiting

Apply to this trial

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

for Clinical Stage III Cutaneous Melanoma AJCC v8

26 locations incl. La Jolla

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05896839·Phase 1, Phase 2·Recruiting

Apply to this trial

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

for Nodular Lymphocyte Predominant B-Cell Lymphoma

Drug: Mosunetuzumab

35 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05886036·Phase 2·Recruiting

Apply to this trial